Test Price
2,800 AED✅ Home Collection Available
CEL Gene MODY8 Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
This advanced genetic test delivers comprehensive sequencing of the CEL gene using next-generation technology to diagnose Maturity-Onset Diabetes of the Young type 8 with diagnostic sensitivity exceeding 99.9%. The service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring complete data security and clinical safety throughout the testing pathway.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed genetics consultant.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) test examines the entire coding region of the CEL gene to identify pathogenic variants responsible for Maturity-Onset Diabetes of the Young type 8 (MODY8), a monogenic diabetes that often mimics Type 1 or Type 2 but requires distinct management. The analysis covers all exons and splice sites, providing a comprehensive assessment that surpasses targeted approaches.
Comparative Analysis: CEL NGS Versus Alternative Methods
| Feature | Our CEL NGS Test | Closest Alternative (Sanger Sequencing Exon 8) |
|---|---|---|
| Methodology | NGS Full Gene Sequencing – covers all exons & splice sites | Sanger sequencing limited to exon 8 hotspot only |
| Diagnostic Sensitivity | >99.9% for all pathogenic variants | ~75% misses mutations outside exon 8 |
| Turnaround Time | 3–4 Weeks (from sample receipt) | 4–6 Weeks |
| Sample Options | Blood, Extracted DNA, or single drop on FTA Card | Blood or DNA only |
| Post-Test Support | Included Telephonic Clinical Guidance by DHA-licensed genetics consultant | Report only |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I consider this NGS-based CEL gene test a cornerstone for accurate subtyping of monogenic diabetes. A positive result enables targeted therapeutic adjustments and informs family screening, while a negative finding does not exclude other genetic or autoimmune diabetes forms. Patients must continue all prescribed medications unless explicitly advised otherwise by their managing physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue or alter any prescribed diabetes medication without first consulting your treating physician. Genetic testing results should guide clinical decisions only under the supervision of a qualified healthcare provider.
Safety & Exclusion Criteria
- Exclusion Criteria: Patients with severe anemia (Hb < 8 g/dL) or active untreated systemic infection should postpone sample collection on physician's advice.
- ER Red Flags: If you experience signs of diabetic ketoacidosis (fruity breath, vomiting, confusion) or extreme hyperglycemic crisis, seek emergency department care immediately before proceeding with genetic testing.
- Pediatric & Vulnerable Populations: All genetic testing for minors requires guardian consent and pre-test genetic counselling, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the CEL gene and why is testing for MODY type 8 important?
This NGS test identifies pathogenic CEL variants to confirm MODY8, distinguishing it from common diabetes types. MODY8 is caused by mutations in the CEL gene that impair insulin secretion. Unlike Type 1 or Type 2 diabetes, MODY8 often responds to specific oral therapies and carries implications for family members, making precise diagnosis essential for optimal management.
2. How is the test performed and what sample types are accepted?
We accept whole blood, previously extracted DNA, or a single dried blood spot on an FTA card. A trained phlebotomist collects a small blood sample during VIP Mobile Phlebotomy visits, which are available daily from 8 AM to 11 PM. All collection kits are ISO-certified for temperature-controlled cold-chain transport to preserve nucleic acid integrity.
3. What does a positive result mean for my treatment and my family?
A detected pathogenic variant confirms MODY8, which often allows transition from insulin to sulfonylureas or other oral agents under medical supervision. Because the condition follows an autosomal dominant inheritance pattern, first-degree relatives have a 50% risk of carrying the same variant. We strongly recommend genetic counselling and cascade family testing after a positive result.
4. How long does it take to receive results and how will they be delivered?
The standard turnaround time is 3 to 4 weeks from the date of sample receipt at the laboratory. Results are delivered electronically via a secure portal and are accompanied by a telephonic consultation with a DHA-licensed genetics consultant who explains the findings and provides clinical recommendations.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This testing service operates under DHA Facility License Number 1143 and adheres to all applicable UAE federal laws governing medical practice and data protection.
Data Privacy: All patient information and genetic data are processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Health Information Security: Clinical data handling follows Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring encrypted storage and controlled access.
Medical Liability: All clinical procedures and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | CEL Gene MODY8 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | E13.9 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians